title: [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
abstract: The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symptoms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
authors.affiliation: Klinik for Klinisk Fysiologi, Nuklearmedicin & PET, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. liselotte.hoejgaard@rh.regionh.dk.
authors.forename: Jann
authors.initials: J
authors.lastname: Mortensen
authors.forename: Liselotte
authors.initials: L
authors.lastname: Højgaard
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011874:Radiometry; D011883:Radium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium